Seeking Alpha

Merrimack drug gets two FDA orphan drug designations

  • Merrimack Pharma's (MACK +2.7%) MM-111 bispecific antibody has received FDA orphan drug designations for the treatment of esophageal cancer, as well as for gastric and gastroesophageal junction cancers.
  • The two designations could provide Merrimack with seven-year marketing exclusivity for MM-111 and with other benefits if the FDA authorizes the drug. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs